Taken together, these findings have demonstrated that LGR5+ AM-EpiSCs can surmount resistance to the BRAFV600E inhibitor (PLX4032) and these PLX4032-resistant LGR5+ AM-EpiSCs are endowed with stem cell properties and an intermediate EMT phenotype with enhanced capacity for tumor organoid formation. Here, LGR5 is linked to neoplasm.